Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Mitsubishi Tanabe to Develop Mobile App for Depression Treatment
September 3, 2020
- LTL Pharma to License Dellegra AG to Nichi-Iko, Eyeing December Rollout
September 3, 2020
- Mitsubishi Tanabe’s HIF-PH Inhibitor Hit by Shortage Days after Launch on Better-than-Expected Demand
September 2, 2020
- Janssen Launches Japan PI Study for Coronavirus Vaccine
September 2, 2020
- Gilead Revises Veklury Label Warning of Coadministration with Hydroxychloroquine or Chloroquine
September 2, 2020
- Taisho, Takeda to Wind Up Japan Distribution Deal for Biofermin’s Prescription Drugs
September 2, 2020
- Fujifilm Files Radiopharmaceutical Drug F-1515 in Japan
September 1, 2020
- Japan Sees Showdown of 3 HIF-PH Inhibitors as 2 New Drugs Enter Market
September 1, 2020
- Sanofi’s Sarclisa Hits Japan Market, Zeria Launches Ferinject
September 1, 2020
- Edoxaban Hits PIII Goal in Very Elderly Patients: Daiichi Sankyo
September 1, 2020
- Sales Rep Promotions Up in July, but Online Channels Down: Intage
August 31, 2020
- Shionogi Pharma Files Baktar Small-Sized Tablets to Improve Compliance in Children
August 31, 2020
- Nichi-Iko to Revamp Quality Control System after Massive Recalls by Leveraging Teva Takeda Plant
August 28, 2020
- MEDRx/D. Western Therapeutics’ Lidocaine Tape Formulation Filed for Post-Herpetic Neuralgia in US
August 28, 2020
- 2 More HIF-PH Inhibitors, Enerzair, Enspryng and More Now Available in Japan
August 27, 2020
- JCR to Commence Full-Fledged Biz for Lysosomal Storage Disorder Meds in Brazil
August 27, 2020
- Kowa’s Glaucoma Med Glanatec Approved in Thailand
August 27, 2020
- As Entresto Hits Japan Market, Novartis Poised to Tap All Channels to Push Global Blockbuster
August 26, 2020
- Carna Bio Starts First-in-Human Trial for BTK Inhibitor
August 26, 2020
- Sanwa Kagaku Files SHPT Med for Japan Approval
August 26, 2020
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…